galectin therapeutics inc (GALT) Key Developments
Galectin Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 10 15
Galectin Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total operating loss of $4.657 million compared to $3.375 million a year ago. Net loss applicable to common stock was $4.931 million or $0.21 per diluted share compared to $3.731 million or $0.17 per diluted share a year ago.
For six months, the company reported total operating loss of $9.497 million compared to $8.219 million a year ago. Net loss applicable to common stock was $10.005 million or $0.43 per diluted share compared to $9.139 million or $0.42 per diluted share a year ago.
Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02
Aug 2 15
Exalenz Bioscience Ltd. announced that it received FDA approval for a joint clinical trial with Galectin Therapeutics Inc. The company's product, the BreathID, will be used to track and diagnose patients in a second-stage clinical trial of GR-MD-02, an experimental treatment for liver cirrhosis caused by NASH (fatty liver disease). Galectin Therapeutics is conducting a multicenter, double-blind, placebo-controlled Phase 2 trial with 156 patients to evaluate the safety and effect of the drug.
Galectin Therapeutics Inc. Appoints Adam E. Allgood, Pharm.D., R.Ph., as Executive Director of Clinical Development
Jul 15 15
Galectin Therapeutics Inc. announced the appointment of Adam E. Allgood, Pharm.D., R.Ph. as executive director of clinical development, effective immediately. Dr. Allgood most recently was associate director of global pharmaceutical regulatory affairs at UCB Inc.
Galectin Therapeutics, Inc. Initiates Enrollment for GR-MD-02 Phase 2 Clinical Trial in Nash with Cirrhosis
Jun 29 15
Galectin Therapeutics, Inc. announced the screening of the first five patients in its Phase 2 clinical trial with GR-MD-02 in nonalcoholic steatohepatitis (NASH) with cirrhosis. This study, the NASH-CX trial, is a multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis.
Galectin Therapeutics, Inc.(NasdaqCM:GALT) dropped from Russell 2000 Index
Jun 29 15
Galectin Therapeutics, Inc. will be removed from Russell 2000 Index